Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant

Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant

Zheng Zhao,1 Zhangjun Song,2 Xuwei Wang,3 Haifeng Sun,1 Xiaomin Yang,2 Yong Yuan,4 Pan Yu3 1Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital, 2Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi’an, 3Marketing Department, Novogene Bioinformatics Institute...

Full description

Bibliographic Details
Main Authors: Zhao Z, Song ZJ, Wang XW, Sun HF, Yang XM, Yuan Y, Yu P
Format: Article
Language:English
Published: Dove Medical Press 2017-08-01
Series:OncoTargets and Therapy
Subjects:
SLC34A2-ROS1 fusion
crizotinib
lung adenocarcinoma
next-generation sequencing
Online Access:https://www.dovepress.com/response-to-crizotinib-in-a-lung-adenocarcinoma-patient-harboring-a-no-peer-reviewed-article-OTT
id doaj-2f127f1e9e56471a8ec73e5f3c1300f1
record_format Article
spelling doaj-2f127f1e9e56471a8ec73e5f3c1300f12020-11-24T23:16:21ZengDove Medical PressOncoTargets and Therapy1178-69302017-08-01Volume 104129413334353Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variantZhao ZSong ZJWang XWSun HFYang XMYuan YYu PZheng Zhao,1 Zhangjun Song,2 Xuwei Wang,3 Haifeng Sun,1 Xiaomin Yang,2 Yong Yuan,4 Pan Yu3 1Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital, 2Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi’an, 3Marketing Department, Novogene Bioinformatics Institute, Beijing, 4Pathology Department, Shannxi Provincial Cancer Hospital, Xi’an, People’s Republic of China Abstract: ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant, which was different from the two common SLC34A2-ROS1 fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal. Keywords: SLC34A2-ROS1 fusion, crizotinib, lung adenocarcinoma, next-generation sequencinghttps://www.dovepress.com/response-to-crizotinib-in-a-lung-adenocarcinoma-patient-harboring-a-no-peer-reviewed-article-OTTSLC34A2-ROS1 fusioncrizotiniblung adenocarcinomanext-generation sequencing
collection DOAJ
language English
format Article
sources DOAJ
author Zhao Z
Song ZJ
Wang XW
Sun HF
Yang XM
Yuan Y
Yu P
spellingShingle Zhao Z
Song ZJ
Wang XW
Sun HF
Yang XM
Yuan Y
Yu P
Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
OncoTargets and Therapy
SLC34A2-ROS1 fusion
crizotinib
lung adenocarcinoma
next-generation sequencing
author_facet Zhao Z
Song ZJ
Wang XW
Sun HF
Yang XM
Yuan Y
Yu P
author_sort Zhao Z
title Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
title_short Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
title_full Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
title_fullStr Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
title_full_unstemmed Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
title_sort response to crizotinib in a lung adenocarcinoma patient harboring a novel slc34a2-ros1 fusion variant
publisher Dove Medical Press
series OncoTargets and Therapy
issn 1178-6930
publishDate 2017-08-01
description Zheng Zhao,1 Zhangjun Song,2 Xuwei Wang,3 Haifeng Sun,1 Xiaomin Yang,2 Yong Yuan,4 Pan Yu3 1Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital, 2Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi’an, 3Marketing Department, Novogene Bioinformatics Institute, Beijing, 4Pathology Department, Shannxi Provincial Cancer Hospital, Xi’an, People’s Republic of China Abstract: ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant, which was different from the two common SLC34A2-ROS1 fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal. Keywords: SLC34A2-ROS1 fusion, crizotinib, lung adenocarcinoma, next-generation sequencing
topic SLC34A2-ROS1 fusion
crizotinib
lung adenocarcinoma
next-generation sequencing
url https://www.dovepress.com/response-to-crizotinib-in-a-lung-adenocarcinoma-patient-harboring-a-no-peer-reviewed-article-OTT
work_keys_str_mv AT zhaoz responsetocrizotinibinalungadenocarcinomapatientharboringanovelslc34a2ros1fusionvariant
AT songzj responsetocrizotinibinalungadenocarcinomapatientharboringanovelslc34a2ros1fusionvariant
AT wangxw responsetocrizotinibinalungadenocarcinomapatientharboringanovelslc34a2ros1fusionvariant
AT sunhf responsetocrizotinibinalungadenocarcinomapatientharboringanovelslc34a2ros1fusionvariant
AT yangxm responsetocrizotinibinalungadenocarcinomapatientharboringanovelslc34a2ros1fusionvariant
AT yuany responsetocrizotinibinalungadenocarcinomapatientharboringanovelslc34a2ros1fusionvariant
AT yup responsetocrizotinibinalungadenocarcinomapatientharboringanovelslc34a2ros1fusionvariant
_version_ 1725587431923646464

Similar Items